Intuity Medical and embecta Launch Commercial Collaboration, Expanding Access to Self-Management Innovations for People With Diabetes

Rhea-AI Summary

Embecta Corp. (EMBC) and Intuity Medical announced a co-promotional agreement to market the POGO Automatic® Blood Glucose Monitoring System across the U.S., effective immediately. Embecta, a leader in diabetes care following its spin-off from BD, aims to enhance diabetes management solutions with this innovative device. POGO Automatic simplifies blood glucose testing using a 10-test cartridge technology, making it the only FDA-cleared automatic blood glucose monitor. This partnership expands Embecta's offerings while supporting Intuity's mission to improve diabetes care.

Positive

• Co-promotional agreement with Intuity Medical enhances product offerings for Embecta.
• POGO Automatic simplifies glucose monitoring, expanding Embecta's innovative technologies.
• Strengthens Embecta's market position following its recent spin-off from BD.

Negative

• None.

FREMONT, Calif. and PARSIPPANY, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Intuity Medical, Inc. and Embecta Corp. (“embecta”) (NASDAQ: EMBC) today announced they have signed a co-promotional agreement under which embecta sales representatives will be able to promote Intuity Medical’s innovative POGO Automatic® Blood Glucose Monitoring System to healthcare professionals they call on within the U.S., effective immediately.

Both companies are dedicated to improving the lives of people with diabetes. Having spun off from BD (Becton, Dickinson and Company) in April of this year, embecta is one of the world’s largest pure-play diabetes companies and, with a nearly 100-year history of leadership in insulin delivery, well established across the U.S. market. Intuity Medical is a medical technology company focused on the development and commercialization of seamless and intuitive blood glucose monitoring solutions.

“We are excited to partner with an established leader like embecta that has such extensive experience serving people with diabetes,” said George Zamanakos, President and CEO of Intuity Medical. “Working closely with the embecta team will help us expand where we’re able to offer POGO Automatic, giving a new option for simplifying diabetes to millions of people currently relying on conventional blood glucose meters.”

With its 10-test cartridge technology, POGO Automatic is the only FDA-cleared automatic blood glucose monitor (ABGM) that lances, collects blood, and produces a glucose result at the push of one button, ending the need to individually load and then dispose of lancets and test strips. Being able to offer POGO Automatic will expand the innovation and breadth of embecta’s diabetes care offerings.

“The agreement to promote POGO Automatic to healthcare professionals not only enables us to expand our offerings to physicians we call on, but it does so within an innovative new category,” said Tom Blount, Senior Vice President and President, North America, for embecta. “Automatic blood glucose monitoring is transforming this vital aspect of self-management into something truly seamless and simple for people with diabetes.”

About Intuity Medical, Inc.

Intuity Medical, Inc. is a commercial-stage medical technology company focused on developing innovative solutions to improve the health and quality of life of people with diabetes. Headquartered in Fremont, California, the company strives to simplify diabetes management and was founded with the mission of making life with diabetes easier. Intuity Medical’s POGO Automatic® Blood Glucose Monitoring System is the only FDA-cleared automatic blood glucose monitoring system that lances and collects blood in just one step with 10-test cartridge technology, ending the need to individually load lancets and test strips (as required by conventional blood glucose meters). POGO Automatic delivers a much simplified and discreet blood glucose testing experience that is less disruptive to the everyday lives of people with diabetes. To learn more, please visit www.presspogo.com.

About embecta

embecta, formerly part of BD (Becton, Dickinson and Company), is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com.

CONTACTS

Media (for Intuity Medical):
Jeff Christensen
831-566-0275
publicrelations@intuitymedical.com

Media (for embecta):
Christian Glazar
Sr. Director, Corporate Communications
908-821-6922
Contact Media Relations 

embecta Investors:
Pravesh Khandelwal
VP, Head of Investor Relations
551-264-6547
Contact IR

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3dad0bdb-c92d-4dd4-834e-12f508ea494d

FAQ

What is the significance of the co-promotional agreement between Embecta and Intuity Medical?

The co-promotional agreement allows Embecta's sales team to promote Intuity Medical's POGO Automatic Blood Glucose Monitoring System, enhancing Embecta's product offerings in diabetes care.

How does the POGO Automatic Blood Glucose Monitoring System work?

The POGO Automatic uses a 10-test cartridge technology to lance, collect blood, and provide glucose results at the push of a button, eliminating the need for separate lancets and test strips.

When did the co-promotion agreement between Embecta and Intuity Medical take effect?

The co-promotion agreement became effective immediately upon announcement on November 7, 2022.

What is the market background for Embecta following its spin-off from BD?

Embecta, now one of the largest pure-play diabetes companies, leverages nearly 100 years of experience in insulin delivery to cater to the diabetes market effectively.

How does the POGO Automatic benefit people with diabetes?

The POGO Automatic offers a simplified and discreet blood glucose testing experience, making diabetes management less disruptive for users.